Prolynx
Dr. Peter Houghton received his bachelor's in Pharmacy from the University of Bradford, and his Ph.D. in Biochemistry/Pharmacology from the University of London, Institute of Cancer Research, Surrey, England. In 2014, Dr. Houghton became Director of the Greehey Children's Cancer Research Institute (GCCRI), and holder of the Greehey Distinguished Chair for the Children's Cancer Research Institute. Previously, he was Director of the Center for Childhood Cancer holding the Elizabeth M. & Richard M. Ross Endowed Chair in Pediatric Research. Prior to Nationwide Children's Hospital, Dr. Houghton held various positions at St. Jude Children's Research Hospital, Memphis, TN. Dr. Houghton's research has been focused on developing relevant models of rare childhood cancer that have been useful in identifying novel drugs (e.g. camptothecins) and understanding the biology of these tumors. Dr. Houghton serves as a member of the Steering Committee, Phase I Consortium, and the Developmental Therapeutics Committee, of the Children's Oncology Group.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
Prolynx
ProLynx (San Francisco, CA), founded in 2009 by Daniel V. Santi, M.D., Ph.D., and Gary W. Ashley, Ph.D., has developed advanced linker technologies and a facile, transformative platform for controlled release of therapeutics from circulating and fixed macromolecular conjugates.